All In Biotech

Drug Trial Radar · NCT07844772

Serum Substance P, Neuropathic Pain, and Central Sensitization Across Treatment Groups in Chronic Plaque Psoriasis

Evaluation of the Association of Serum Substance P Levels With Neuropathic Pain, Central Sensitization, Disease Severity, and Quality of Life Across Different Treatment Groups in Patients With Chronic Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Jun 11, 2026

Primary completion

Dec 2026

Study completion Jan 2027

Sponsor

Lead sponsor
Istanbul Training and Research HospitalGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Sep 28, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this observational study is to better understand whether blood levels of Substance P are related to pain, itching, altered pain sensations, central sensitization, psoriasis severity, and quality of life in adults with chronic plaque psoriasis. The main questions this study aims to answer are: Are serum Substance P levels associated with neuropathic pain features, central sensitization, psoriasis severity, pain, itching, and quality of life? Do serum Substance P levels and these clinical features differ among patients receiving different psoriasis treatments? Researchers will compare three groups of patients: those receiving IL-17 inhibitor treatment, those receiving conventional systemic treatment with methotrexate or acitretin, and those receiving topical treatment only or no current treatment. Participants will: Have their psoriasis severity assessed and complete questionnaires about pain, itching, central sensitization, and quality of life. Undergo a neurological examination. Participants who report pain will also be evaluated for neuropathic pain features using the DN4 questionnaire. Provide a blood sample for measurement of serum Substance P and routine laboratory tests. Undergo electromyography and nerve conduction studies if peripheral neuropathy is suspected during the neurological evaluation. No treatment will be assigned or changed as part of this study.

Conditions

  • Chronic Plaque-type Psoriasis

Interventions

  • IL-17 Inhibitor TherapyBiological

    Exposure to IL-17 inhibitor therapy prescribed as part of routine clinical care for chronic plaque psoriasis. Treatment is not assigned, initiated, or modified by the study. Participants are classified according to their current treatment at the time of study assessment.

  • Conventional Systemic TherapyDrug

    Exposure to conventional systemic therapy with methotrexate or acitretin prescribed as part of routine clinical care for chronic plaque psoriasis. Treatment is not assigned, initiated, or modified by the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Association Between Serum Substance P Levels and DN4 ScoreTime frame: Baseline (Day 1)
  2. Association Between Serum Substance P Levels and Central Sensitization Inventory ScoreTime frame: Baseline (Day 1)
  3. Association Between Serum Substance P Levels and Psoriasis SeverityTime frame: Baseline (Day 1)
  4. Association Between Serum Substance P Levels and Pain IntensityTime frame: Baseline (Day 1)
  5. Association Between Serum Substance P Levels and Pruritus IntensityTime frame: Baseline (Day 1)
  6. Association Between Serum Substance P Levels and Dermatology-Related Quality of LifeTime frame: Baseline (Day 1)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Istanbul Training and Research Hospital

    Istanbul, Istanbul, Turkey (Türkiye) · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.